BioNotebook: TPG's Aptalis files for $500 million IPO, Shire extends offer for ViroPharma
This article was originally published in Scrip
Executive Summary
The days before and after Christmas weren’t completely devoid of news. A pair of companies announced plans for initial public offerings, including an IPO for private equity-backed Aptalis. An antibacterial drug developer raised $18 million in a private financing, while a company testing a multiple sclerosis therapy raised $8 million in a secondary offering. A small oncology specialist said it raised more than $3 million in an add-on offering. And Shire extended its tender offer for the $4.2 billion takeover of ViroPharma.
You may also be interested in...
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen's Scangos sees potential to dominate hemophilia market
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.